CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer

Only a limited proportion of patients with non-small cell lung cancer respond to anti-PD-1/PD-L1 immunotherapy. Here, the authors show that in autochthonous models of KRAS-mutated lung cancer, CCL7 promotes cDC1 infiltration into the lungs, sustaining antitumor immune responses and potentiating anti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Man Zhang, Wei Yang, Peng Wang, Yu Deng, Yu-Ting Dong, Fang-Fang Liu, Rui Huang, Peng Zhang, Ya-Qi Duan, Xin-Dong Liu, Dandan Lin, Qian Chu, Bo Zhong
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/6ad6962bb938456fbf0d46217e9f5191
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6ad6962bb938456fbf0d46217e9f5191
record_format	dspace
spelling	oai:doaj.org-article:6ad6962bb938456fbf0d46217e9f51912021-12-02T16:49:30ZCCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer10.1038/s41467-020-19973-62041-1723https://doaj.org/article/6ad6962bb938456fbf0d46217e9f51912020-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-19973-6https://doaj.org/toc/2041-1723Only a limited proportion of patients with non-small cell lung cancer respond to anti-PD-1/PD-L1 immunotherapy. Here, the authors show that in autochthonous models of KRAS-mutated lung cancer, CCL7 promotes cDC1 infiltration into the lungs, sustaining antitumor immune responses and potentiating anti-PD1 treatment efficacy.Man ZhangWei YangPeng WangYu DengYu-Ting DongFang-Fang LiuRui HuangPeng ZhangYa-Qi DuanXin-Dong LiuDandan LinQian ChuBo ZhongNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Man Zhang Wei Yang Peng Wang Yu Deng Yu-Ting Dong Fang-Fang Liu Rui Huang Peng Zhang Ya-Qi Duan Xin-Dong Liu Dandan Lin Qian Chu Bo Zhong CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
description	Only a limited proportion of patients with non-small cell lung cancer respond to anti-PD-1/PD-L1 immunotherapy. Here, the authors show that in autochthonous models of KRAS-mutated lung cancer, CCL7 promotes cDC1 infiltration into the lungs, sustaining antitumor immune responses and potentiating anti-PD1 treatment efficacy.
format	article
author	Man Zhang Wei Yang Peng Wang Yu Deng Yu-Ting Dong Fang-Fang Liu Rui Huang Peng Zhang Ya-Qi Duan Xin-Dong Liu Dandan Lin Qian Chu Bo Zhong
author_facet	Man Zhang Wei Yang Peng Wang Yu Deng Yu-Ting Dong Fang-Fang Liu Rui Huang Peng Zhang Ya-Qi Duan Xin-Dong Liu Dandan Lin Qian Chu Bo Zhong
author_sort	Man Zhang
title	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
title_short	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
title_full	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
title_fullStr	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
title_full_unstemmed	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
title_sort	ccl7 recruits cdc1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/6ad6962bb938456fbf0d46217e9f5191
work_keys_str_mv	AT manzhang ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT weiyang ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT pengwang ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT yudeng ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT yutingdong ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT fangfangliu ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT ruihuang ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT pengzhang ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT yaqiduan ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT xindongliu ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT dandanlin ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT qianchu ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer AT bozhong ccl7recruitscdc1topromoteantitumorimmunityandfacilitatecheckpointimmunotherapytononsmallcelllungcancer
_version_	1718383282230394880

CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer

Ejemplares similares